Donaldson Inc Stock Price, News & Analysis

Donaldson Company, Inc. (NYSE:DCI) has announced that DonorsChoose, an education equity organization, is the recipient of the Donaldson Foundation $100K Challenge grant. This year's theme focused on childhood education. The grant will be used to match donations made by the public for DonorsChoose projects in communities where Donaldson operates in the United States, effectively doubling the impact.

DonorsChoose was selected through a voting process involving Donaldson's U.S.-based employees. Two other finalists, Little Free Library and United Through Reading, will each receive $10,000 to support their missions. In fiscal year 2023, the Donaldson Foundation distributed $1.2 million to nonprofit organizations, emphasizing its commitment to supporting education initiatives and strengthening communities.

Donaldson's Univercells Technologies business has expanded its evaluation agreement with the Gene Therapy Program (GTP) at the University of Pennsylvania. The collaboration aims to assess the scalability of gene therapy production using Univercells Technologies' bioreactors, specifically the scale-X™ nitro 600 m2 bioreactor. This partnership seeks to increase production per batch and potentially reduce cost of goods sold (COGS) for gene therapies.

The agreement highlights the importance of industry-academic partnerships in advancing gene therapy development and commercialization. Univercells Technologies' bioreactor, initially developed with support from the Bill and Melinda Gates Foundation, is now being applied to enhance viral vector accessibility for gene therapies. This collaboration aligns with GTP's vision of making gene therapies for rare diseases more accessible worldwide.

Donaldson Company (NYSE: DCI), a leading global provider of filtration solutions, has announced key leadership changes effective August 1, 2024. Andrew Dahlgren, currently President of Life Sciences, will become President of Mobile Solutions. Richard Lewis, currently President of Mobile Solutions, will take over as President of Life Sciences. These changes support Donaldson's strategic initiatives and organizational development goals, aiming toward fiscal 2026 financial targets and 2030 sustainability ambitions. Both leaders, with extensive experience within the company, promise a seamless transition.

Donaldson (NYSE: DCI) reported record sales and earnings for Q3 FY 2024. Sales increased 6.0% year-over-year to $927.9 million. GAAP net earnings reached $113.5 million, with EPS growing by 21.7% to $0.92. Gross margin improved to 35.6%, while operating margin increased to 15.5%. Operating expenses rose due to investments in Life Sciences. Mobile Solutions and Industrial Solutions saw sales growth, but On-Road and Off-Road sales declined. Life Sciences sales surged by 24.2%, driven by Bioprocessing Equipment. Fiscal 2024 EPS guidance was raised to $3.33-$3.39. Donaldson also repurchased 1.5% of its shares for $114.0 million and paid $90.3 million in dividends.

Donaldson Company (NYSE: DCI) announced an 8.0% increase in its quarterly cash dividend, raising it from 25.0 cents to 27.0 cents per share. This dividend is payable on June 28, 2024, to shareholders of record by June 17, 2024. The company is part of the S&P High-Yield Dividend Aristocrats Index and has raised its dividend annually for 28 consecutive years. Donaldson has been paying a cash dividend every quarter for the past 68 years. Founded in 1915, Donaldson is a global leader in filtration products and solutions, serving various industries with operations in over 140 locations across six continents.

Donaldson Company (NYSE: DCI) announced that Tod Carpenter, its chairman, president, and CEO, will present at two upcoming conferences: the Stifel 2024 Cross Sector Insight Conference on June 5, 2024, at 8:10 a.m. CT, and the William Blair 44th Annual Growth Stock Conference on June 6, 2024, at 10:00 a.m. CT.

Both presentations will be webcast live and available for replay for approximately 90 days on Donaldson’s Investor Relations website. Donaldson is a global leader in filtration products and solutions, serving various industries with a focus on Mobile Solutions, Industrial Solutions, and Life Sciences.

Donaldson celebrated its 2024 patent recipients and Inventor Award winners, recognizing 100 individuals for their contributions to filtration technology. The company, with over 4,373 active patents and 190 new patents awarded last fiscal year, continues its legacy of innovation. Key awards include the Technology Achievement Award for the Hydraulic Deaeration team, Technology Champion Award to Kristoff Decoster, Emerging Innovator Award to Michael Dzuricky, Richard M. Negri Manufacturing Excellence Award to Steve Dodd, and Frank A. Donaldson Award to Ben Nelson. Donaldson remains a global leader in filtration solutions, serving diverse industries through its Mobile Solutions, Industrial Solutions, and Life Sciences segments.

Donaldson and PolyPeptide have partnered to enhance sustainability in peptide manufacturing by developing a solvent recovery system for peptide purification. Leveraging Donaldson's filtration expertise and PolyPeptide's peptide synthesis skill, the technology reclaims and purifies acetonitrile, significantly reducing solvent consumption and waste. The system, piloted at PolyPeptide's Torrance site, reduces environmental impact by reclaiming solvents typically incinerated post-use. This collaboration aligns with both companies' commitment to sustainable manufacturing and green chemistry principles.

Donaldson Company, Inc. (NYSE: DCI) is developing an integrated upstream and downstream platform for viral vector manufacturing, focusing on lentivirus (LV) production to improve recoveries and reduce manufacturing complexity. The platform aims to accelerate process development timelines and lower costs in the production of cell and gene therapies. Univercells Technologies and Isolere Bio are collaborating on this initiative, with Isolere's IsoTag LV affinity purification reagent offering high functional recoveries and purity, while Univercells Technologies' scale-X bioreactor demonstrates high yields of LV in perfusion mode. The project is a strategic move by Donaldson to enhance its presence in the bioprocessing space through innovative acquisitions.